[1] Dai L,Renp P,Liu M,et al.Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma. Clin Immunol,2014,152(8):127-139. [2] 王琴,张东成,董超,等. 三维适形放疗放射野布局对治疗原发性肝癌患者放射性肝损伤的影响.实用肝脏病杂志,2017,20(3):366-367. [3] Lok AS, Sterling RK, Everhart JE, et al.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology,2010,138(4):493-502. [4] Ida S,Ozaki N,Araki K,et al.SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer. Mol Cancer Res,2015,13(7):1130-1130. [5] 滕梁红,高巍,卢德宏,等.ERG和SPINK1蛋白在前列腺癌中表达的相互排斥性及其与预后的相关性.中华病理学杂志,2014,43(3):149-153. [6] Sakamoto M.Pathology of early hepatocellular carcinoma. Hepatol Res,2007,37(2):S135-S138. [7] Yamazaki Y, Kakizaki S, Sohara N,et al.Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis,and findings of a patient survival analysis.Dig Dis Sci,2007,52(4):1103-1107. [8] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会等.原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21(3):145-151. [9] Butler SL,Dong H,Cardona D,et al.The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest,2008,88(2):78-88. [10] Joo M, Chi JG,Lee H.Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci,2005,20(4):829-834. [11] 曹光材,白江江,戴阿利,等. 胆管癌组织紧密连结蛋白18、丝氨酸蛋白酶抑制剂和p53蛋白表达及其临床意义.实用肝脏病杂志,2017,20(3):312-315. [12] 丁辉,李鹏飞,杨玉秀,等.丝氨酸蛋白酶抑制剂Kazal1型基因N34S突变与慢性胰腺炎发病的关系.中华实验外科杂志,2014,31(12):2879-2881. [13] Shafizadeh N, Ferrell LD,Kakar S.Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol,2008,21(1):1011-1018. [14] Kakar S,Gown AM,Goodman ZD,et al.Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med,2007,131(9):1648-1654. [15] Jobst J,Vogel U,Scheurlen M,et al.Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma:potential implications for viral hepatocarcinogenesis.Oncol Res Treat,2014,37(12):732-738. [16] Marshall A,Lukk M,Kutter C,et al.Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.PloS one,2013,8(3):e59459. [17] Tackel-Horne D,Goodman MD, Williams AJ,et al.Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer,2001,92(11):395-405. [18] Hass HG,Hass H,Jobst J,et al.Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma. Anticancer Res,2015,35(4):2021-2028. [19] 黄宇博,吕勋,蒋振华,等.肝细胞癌患者血浆Ⅰ型丝氨酸蛋白酶抑制剂kazal表达及意义.中华实用诊断与治疗杂志,2017,31(5):473-475. [20] Tretiakova MS,Shabani-Rad MT,Guggisberg K,et al.Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis. Histopathology,2010,56(5):683-693. [21] 张浩. 肝癌肝动脉栓塞用载药微球的研究现状及进展.医学临床研究,2017,34(2):341-344. [22] 何秀娟,黄庆愿.非小细胞肺癌患者术后组织中丝氨酸蛋白激酶抑制剂kazalⅠ型、CD147和E-cadherin的表达及意义.中国老年学杂志,2015,35(6):1592-1594. [23] 张婧,王军.SPINK1/Spink3的研究进展.大连医科大学学报,2015,37(4):398-402. [24] 蔡春林,邬开朗,祝成亮,等.乙型肝炎病毒对SPINK1表达的影响.中国卫生检验杂志,2016,26(3):364-366. |